Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Probenecid · Benemid, NSC-18786

Small molecule · Inhibitor of urate transporter · developed by Merck

Approved FDA, Apr 1951
MRK Developer
2 Registered trials

What is Probenecid?

Probenecid is a benzoic acid derivative that competitively inhibits urate reabsorption at the proximal renal tubule, increasing urinary uric acid excretion and lowering serum urate. It prevents urate deposition and promotes resolution of existing deposits. Probenecid also modulates organic acid transport in renal tubules.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Benemid, NSC-18786
Drug type
Small molecule
Targets
urate transporter
Mechanism
Inhibitor of urate transporter
Pathways
uric acid excretion
Therapy area
Metabolic
Developer
Merck (MRK)
Also in trials of
VTGN
FDA status
Approved as Benemid (April 26, 1951), NDA007898
UNII
PO572Z7917

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07840612 Phase 1 Healthy Not yet recruiting MRK
NCT05280054 Phase 1 Drug Drug Interaction Unknown VTGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HealthyDrug Drug Interaction

More from Merck

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3 Favezelimab Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Probenecid

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.